TY - JOUR
T1 - Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group
AU - Emile, Jean François
AU - Tisserand, Julie
AU - Bergougnoux, Loic
AU - Nowak, Frédérique
AU - Faucher, Gladwys
AU - Surel, Sylvie
AU - Lamy, Aude
AU - Lecorre, Delphine
AU - Helias-Rodzewicz, Zofia
AU - Hofman, Paul
AU - Sabourin, Jean Christophe
AU - Laurent-Puig, Pierre
AU - Aube, Drs Cécile
AU - Baala, Lebkir
AU - Hattar, Jean Ben
AU - Boyer, Christophe
AU - Charlotte, Frédéric
AU - Cervera, Pascale
AU - Clauser, Eric
AU - De Fraipont, Florence
AU - Dechelotte, Pierre
AU - Delvincourt, Chantal
AU - Denis, Marc
AU - Doucet, Laurent
AU - Durand, Karine
AU - Escande, Fabienne
AU - Ferraro-Peyret, Carole
AU - Galateau-Salle, Françoise
AU - Haratyk, Cécile
AU - Heller, Rémy
AU - Jonveaux, Philippe
AU - Karayan-Tapon, Lucie
AU - Lacave, Roger
AU - Lacroix, Ludovic
AU - Lamant, Laurence
AU - Lamoril, Jérôme
AU - Lamy, Jean
AU - Lemoine, Antoinette
AU - Leroy, Karen
AU - Lizard, Sarab
AU - Lopez-Rios, Fernando
AU - Merkelbach-Bruse, Sabine
AU - Merlin, Jean Louis
AU - Merlio, Jean Philippe
AU - Mourah, Samia
AU - Metellus, Isabelle Nanni
AU - Pages, Jean
AU - Pedeutour, Florence
AU - Peoc'h, Michel
AU - Pretet, Jean Luc
AU - Prunier, Delphine
AU - Rioux-Leclercq, Nathalie
AU - Rouleau, Etienne
AU - Sobol, Hagay
AU - Solassol, Jérôme
AU - Trudel, Stéphanie
AU - Borght, Sabine Vande
AU - Wang, Qing
N1 - Funding Information:
This work was funded by Roche France.
Funding Information:
In 2008, the French National Institute for Cancer (INCa) initiated a nationwide program for the development of regional platforms for molecular pathology testing for cancers [12]. This national network consists of 28 platforms involving 46 laboratories. These laboratories are supported by grants from INCa, and all the tests are performed free of charge. In 2011, 20,761 EGFR tests for lung non-small cell carcinomas and 17,153 KRAS tests for colorectal carcinomas (http://www.e-cancer.fr) were performed. In practical terms, any of the 63,703,191 inhabitants of France (http://www.insee.fr) can benefit from molecular pathology analysis for free, provided it is necessary for treatment, and this nationwide program can thus be considered a success. The French platforms performed 3,479 BRAF tests on melanoma samples in 2011 and 4,629 in 2012.
PY - 2013/10/11
Y1 - 2013/10/11
N2 - Background: Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for BRAF p.V600 were performed in France, in patients with melanomas.Methods: Two batches of unstained melanoma sections were sent, in May and November 2012, to the 46 laboratories supported by the French National Institute of Cancer (INCa). An external quality assessment (EQA) evaluated mutation status, response times and compliance with INCa recommendations.Results: All the French laboratories involved in testing participated in the EQA. Fourteen different methods were used to detect BRAF mutations, most consisting of combinations of in-house techniques. False responses were noted in 25/520 cases (4.8%), 11 of which concerned confusion between p.V600E and p.V600K. Thus, 2.7% of responses would have led to inappropriate treatment. Within six months, mean response times decreased from 22 to 12 days (P<0.001), and the percentage of samples evaluated by a pathologist for tumour cell content increased, from 75.2% to 96.9% (P<0.001).Conclusion: Despite the use of non-certified methods, the false response rate was low. Nationwide EQA can improve the quality of molecular pathology tests on tumours.
AB - Background: Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for BRAF p.V600 were performed in France, in patients with melanomas.Methods: Two batches of unstained melanoma sections were sent, in May and November 2012, to the 46 laboratories supported by the French National Institute of Cancer (INCa). An external quality assessment (EQA) evaluated mutation status, response times and compliance with INCa recommendations.Results: All the French laboratories involved in testing participated in the EQA. Fourteen different methods were used to detect BRAF mutations, most consisting of combinations of in-house techniques. False responses were noted in 25/520 cases (4.8%), 11 of which concerned confusion between p.V600E and p.V600K. Thus, 2.7% of responses would have led to inappropriate treatment. Within six months, mean response times decreased from 22 to 12 days (P<0.001), and the percentage of samples evaluated by a pathologist for tumour cell content increased, from 75.2% to 96.9% (P<0.001).Conclusion: Despite the use of non-certified methods, the false response rate was low. Nationwide EQA can improve the quality of molecular pathology tests on tumours.
UR - http://www.scopus.com/inward/record.url?scp=84885916069&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-13-472
DO - 10.1186/1471-2407-13-472
M3 - Article
C2 - 24119386
AN - SCOPUS:84885916069
SN - 1471-2407
VL - 13
JO - BMC Cancer
JF - BMC Cancer
M1 - 472
ER -